Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Francesca Blasco"'
Autor:
Julien Lescar, Feng Gu, Kah Fei Wan, Francesca Blasco, CongBao Kang, Wai Ling Chan, Wei Liu, Paul W. Smith, Agatha Susila, Bin Zou, Qing Yin Wang, K.L. Yeo, Mei Ding, Chao Shan, Andy M. Yip, Haoying Xu, Hongping Dong, Jing Zou, Suresh B. Lakshminarayana, Ratna Karuna, Pei Yong Shi, Peck Gee Seah
Publikováno v:
Journal of Virology. 89:8233-8244
The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that
Autor:
Hao Ying Xu, Wei Liu, Feng Gu, Bin Zou, Wai Ling Chan, Paul W. Smith, Kah Fei Wan, Ratna Karuna, Agatha Susila, Peck Gee Seah, Andy Yip, Pei Yong Shi, Trixie Wagner, Thierry T. Diagana, Qing Yin Wang, Alex Chao, Mei Ding, Hongping Dong, Seh Yong Leong, Francesca Blasco, Katherine Chan, Shahul Nilar, Ina Dix
Publikováno v:
ACS Medicinal Chemistry Letters. 6:344-348
Spiropyrazolopyridone 1 was identified, as a novel dengue virus (DENV) inhibitor, from a DENV serotype 2 (DENV-2) high-throughput phenotypic screen. As a general trend within this chemical class, chiral resolution of the racemate revealed that R enan
Autor:
Peter Drueckes, Clive Mccarthy, Catherine H. Régnier, Giorgio Ottaviani, Janitha Reetz, Marc Gerspacher, Fabienne Baffert, Francesca Blasco, Philipp Holzer, Christoph Gaul, Julien Scesa, Eric Vangrevelinghe, Pascal Furet, Carole Pissot-Soldermann, Flavio Ossola, Gisele A. Tavares, Thomas Radimerski
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:2609-2613
We have designed and synthesized a novel series of 2,8-diaryl-quinoxalines as Janus kinase 2 inhibitors. Many of the inhibitors show low nanomolar activity against JAK2 and potently suppress proliferation of SET-2 cells in vitro. In addition, compoun
Autor:
Daniel Guthy, Marc Gerspacher, Jasmin Wirth, Robin Alec Fairhurst, Joachim Blanz, Van Huy Luu, Patricia Imbach-Weese, Robert Mah, Christian Schnell, Esther Roehn-Carnemolla, Giorgio Caravatti, Christine Fritsch, Francesca Blasco, Sandrine Desrayaud, Pascal Furet, Dorothee Arz, Mark Knapp
Publikováno v:
Bioorganicmedicinal chemistry letters. 25(17)
A cyclisation within a 4',5-bisthiazole (S)-proline-amide-urea series of selective PI3Kα inhibitors led to a novel 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole tricyclic sub-series. The synthesis and optimisation of this 4,5-dihydrobenzo[1,2-d:3,4-d]bis
Autor:
Ujjini H. Manjunatha, Richard Glynne, John R. Walker, Bee Huat Tan, Paul W. Smith, Srinivasa P. S. Rao, Kelli Kuhen, Pearly Shuyi Ng, Christian G. Noble, Susan W. Barnes, Peter J. Tonge, Seow H. Ng, Suresh B. Lakshminarayana, Ng L. Ma, Ravinder Reddy Kondreddi, Francesca Blasco, Thierry T. Diagana, David Beer, Maxime Herve, Weixuan Yu, Luis R. Camacho
Publikováno v:
Science Translational Medicine. 7
New chemotherapeutic agents are urgently required to combat the global spread of multidrug-resistant tuberculosis (MDR-TB). The mycobacterial enoyl reductase InhA is one of the few clinically validated targets in tuberculosis drug discovery. We repor
Publikováno v:
Bioorganicmedicinal chemistry. 21(11)
There has recently been a burgeoning interest in impeding drug metabolism by replacing hydrogen atoms with deuterium to invoke a kinetic isotope effect. Imatinib, a front-line therapy for both chronic myeloid leukemia and of gastrointestinal stromal
Autor:
Francesca Blasco, Eric Vangrevelinghe, Stephan Ruetz, Marc Lang, Lynda Nolan, Josef Brueggen, Markus Wartmann, Peter Drueckes, Thomas Radimerski, Lorenza Wyder, Alain De Pover, Marc Gerspacher, Gisele A. Tavares, Francesco Hofmann, Joerg Trappe, Patrick Chène, Catherine H. Régnier, Fabienne Baffert, Pascal Furet, Dirk Erdmann, David Ledieu, Carole Pissot-Soldermann
Publikováno v:
Molecular cancer therapeutics. 9(7)
The recent discovery of an acquired activating point mutation in JAK2, substituting valine at amino acid position 617 for phenylalanine, has greatly improved our understanding of the molecular mechanism underlying chronic myeloproliferative neoplasms
Autor:
Helena I. Boshoff, Francesca Blasco, Sindhu Ravindran, Thomas Dick, Mahesh Nanjundappa, Paul C. Ho, Jan Jiricek, Clifton E. Barry, Anne Goh, Joseph Cherian, Ramandeep Singh, Suresh B. Lakshminarayana, Amit Nayyar, Ujjini H. Manjunatha, Meera Gurumurthy
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 8, p e105222 (2014)
PLoS ONE, Vol 9, Iss 8, p e105222 (2014)
PA-824 is a bicyclic 4-nitroimidazole, currently in phase II clinical trials for the treatment of tuberculosis. Dose fractionation pharmacokinetic-pharmacodynamic studies in mice indicated that the driver of PA-824 in vivo efficacy is the time during